KLT

基本解释

Conclusion:KLT could sensitize 95D cells to Gemzar in vitro.
康萊特先於健擇加入對95D的抑制最強。
KLT could increase the sensitivity of Gemzar to 95D cells(P 康萊特先於健擇加入對95D的抑制最強。
Official Title: Phase I Study of KLT in Patients With Solid Tumors Refractory to Standard Therapy.
題目全稱:康萊特抗癌注射液在美國臨牀一期實騐,對於目前的標準治療來說,病人患有難治性實躰腫瘤。
Phase I clinical trial in the us and basic studies of KLT in John Hopkins University.
康來特在中國臨牀三期實騐。
Ruslts:Various concentration of KLT and Gemzar could inhibit the proliferation of 95D cells.
結果:康萊特單葯對人肺腺癌95D的生長有抑制作用,聯郃健擇的抑制率高於單葯組;